 Home > Active Ingredient News > Study of Nervous System > Good news for insomnia patients, CHMP recommends dual-acting orexin receptor antagonist Quviviq

Good news for insomnia patients, CHMP recommends dual-acting orexin receptor antagonist Quviviq

 Last Update: 2022-04-22
 Source: Internet
 Author: User

Tags

hot spot results

balmex adults

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, the European Committee for Medicinal Products for Human Use (CHMP) has recommended Quviviq (daridorexant) as the first dual-acting orexin receptor antagonist in the European Union for the treatment of adult patients with insomnia
.

This notion is supported by pivotal Phase III data recently published in The Lancet Neurology
.

The results showed that daridorexant improved nighttime symptoms and daytime functioning in adults with insomnia in the first and third months compared to placebo

The Lancet results showed that daridorexant 25 mg and 50 mg improved sleep outcomes, and daridorexant 50 mg also improved daytime function in patients with insomnia with a favorable safety profile

Insomnia is a sleep-wake disorder characterized by difficulty falling asleep and/or maintaining sleep despite adequate sleep opportunities, resulting in daytime-related consequences such as fatigue, difficulty concentrating, and irritability
.

Insomnia is one of the most common sleep-wake disorders, and about 30% of adults worldwide have symptoms of insomnia

If approved, Quviviq would not only be the first dual-acting orexin receptor antagonist in Europe, but also the first insomnia drug to improve daytime function in patients
.

In addition, by periodically reassessing treatment needs, Quviviq can be used for long-term treatment, addressing a key limitation of existing therapies

Jean-Paul Clozel, Managing Director and Chief Executive Officer of Idorsia, reviewed this important CHMP approval, explaining: "The CHMP recommendation is an important milestone for Idorsia and an important step towards bringing new treatment options to patients with insomnia in Europe"

Original source:

https:// href="https://" target="_blank" rel="noopener">https:// https:// Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.